ELVN
$41.25+6.59%
Enliven Therapeutics Inc.Stock · HealthcareRussell 2000 · 0.07% of IWMNasdaq Composite · 0.008% of ONEQUS Stock Market · 0.004% of VTIRussell 3000 · 0.003% of IWV
ELVN financial statements
The full income statement, balance sheet, and cash-flow statement for Enliven Therapeutics Inc. (ELVN), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 47.2M2024-09 48.9M2024-12 49.0M2025-03 49.1M2025-06 59.2M2025-09 59.3M2025-12 59.8M2026-03 60.9M2026-06 73.3M+55.1% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 120M+14.4% | 105M+25.2% | 83.5M+115.3% | 38.8M-24.6% | 51.4M+23.4% | ||
| Research & development | 85.9M+6.3% | 80.8M+25.1% | 64.6M+108.2% | 31.0M-19.3% | 38.4M+19.6% | |
| Selling, general & administrative | 33.8M+42.2% | 23.8M+25.4% | 19.0M+144.0% | 7.77M-40.2% | 13.0M+36.2% | |
| General & administrative | 33.8M+42.2% | 23.8M+25.4% | 19.0M+144.0% | 7.77M-40.2% | 13.0M+36.2% | |
| Operating income | -120M-14.4% | -105M-25.2% | -83.5M-115.3% | -38.8M+24.6% | -51.4M-23.4% | |
| Other non-operating income | -49.0K-2350.0% | -2.00K+90.9% | -22.0K | 0.00+100.0% | -175K-20.7% | |
| Pre-tax income | — | — | — | 1.58M+103.1% | -51.4M | |
| Income tax | 0.00-100.0% | 232K | 0.00 | 0.00 | — | |
| -104M-16.5% | -89.0M-24.4% | -71.6M-90.1% | -37.7M+26.7% | -51.4M-24.2% | ||
| Preferred dividends | — | — | — | — | 0.00 | |
| -$1.83+3.2% | -$1.89+6.0% | -$2.01+83.3% | -$12.05-408.4% | -$2.37 | ||
| EPS (basic) | -$1.83+3.2% | -$1.89+6.0% | -$2.01+83.3% | -$12.05-408.4% | -$2.37 | |
| Weighted-avg shares (basic) | 56.7M+20.4% | 47.1M+32.4% | 35.5M+1037.7% | 3.12M-85.6% | 21.7M | |
| Weighted-avg shares (diluted) | 56.7M+20.4% | 47.1M+32.4% | 35.5M+1037.7% | 3.12M-85.6% | 21.7M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 475M+49.3% | 318M+19.5% | 266M+242.3% | 77.8M-16.1% | 92.7M+2.5% | ||
| Cash & equivalents | 98.9M-20.3% | 124M+23.9% | 100M+32.6% | 75.5M+56.4% | 48.3M+1.3% | |
| Short-term investments | 364M+92.1% | 189M+23.7% | 153M | 0.00 | — | |
| Cash & short-term investments | 463M+47.6% | 313M+23.8% | 253M | — | 90.3M+2.4% | |
| Prepaid expenses | 12.3M+164.6% | 4.63M+57.1% | 2.95M+33.0% | 2.22M-8.3% | 2.42M+10.8% | |
| 476M+46.2% | 326M+19.8% | 272M+226.4% | 83.3M-11.1% | 93.6M+3.1% | ||
| Property, plant & equipment | 34.0K-92.6% | 458K-38.3% | 742K-16.6% | 890K+256.0% | 250K-28.4% | |
| Operating lease right-of-use | 383K | 0.00-100.0% | 320K-48.9% | 626K+19.2% | 525K | |
| Long-term investments | — | — | — | 0.00 | — | |
| Other non-current assets | 656K-90.9% | 7.17M+75.4% | 4.09M | 0.00-100.0% | 175K+98.9% | |
| 16.6M+4.1% | 15.9M-38.5% | 25.9M+166.5% | 9.71M+34.7% | 7.21M+15.4% | ||
| Accounts payable | 2.16M+60.9% | 1.34M+152.3% | 532K-84.5% | 3.44M+45.7% | 2.36M+19.7% | |
| Accrued liabilities | — | — | — | 1.68M-63.5% | 4.60M+7.7% | |
| Current lease liability | 399K | — | 335K | — | 246K | |
| 16.6M+4.1% | 15.9M-38.7% | 26.0M+150.3% | 10.4M+36.2% | 7.62M+18.9% | ||
| Non-current lease liability | 0.00 | — | 0.00 | — | 406K | |
| Operating lease liability (total) | 399K | — | 335K | — | 652K | |
| Other non-current liabilities | 0.00 | 0.00-100.0% | 67.0K-89.8% | 659K | — | |
| 460M+48.3% | 310M+26.0% | 246M+420.1% | -76.8M-79.1% | -42.9M-150.8% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | — | — | |
| Common stock | 59.0K+20.4% | 49.0K+19.5% | 41.0K+4000.0% | 1.00K-96.3% | 27.0K+50.0% | |
| Additional paid-in capital | 806M+45.8% | 553M+38.2% | 400M+6527.6% | 6.04M-97.4% | 234M+29.4% | |
| Retained earnings | -347M-42.6% | -243M-57.6% | -154M-86.4% | -82.9M+43.8% | -147M-53.5% | |
| Accumulated other comprehensive income | 334K+507.3% | 55.0K-61.0% | 141K | 0.00+100.0% | -16.0K-500.0% | |
| Total liabilities & equity | 476M+46.2% | 326M+19.8% | 272M+226.4% | 83.3M-11.1% | 93.6M+3.1% | |
| Common shares issued | 59.4M+21.5% | 48.9M+18.5% | 41.3M+1056.6% | 3.57M-86.4% | 26.3M+49.8% | |
| Common shares outstanding | 59.4M+21.5% | 48.9M+18.5% | 41.3M+1056.6% | 3.57M-86.4% | 26.3M+49.8% | |
| Shares outstanding (cover) | 59.8M+22.0% | 49.0M+18.5% | 41.3M+57.6% | 26.2M-0.2% | 26.3M+49.6% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -70.3M+3.9% | -73.2M-19.5% | -61.3M-91.0% | -32.1M+31.4% | -46.8M-25.1% | ||
| Depreciation & amortization | 300K+0.0% | 300K+0.0% | 300K+50.0% | 200K+102.0% | 99.0K+2.1% | |
| Share-based compensation | 34.0M+68.6% | 20.2M+56.2% | 12.9M+304.7% | 3.19M-17.0% | 3.85M+72.3% | |
| Change in payables | 817K+0.9% | 810K+136.0% | -2.25M-647.4% | 411K+5.7% | 389K+24.3% | |
| -174M-382.9% | -36.0M+75.7% | -148M-24150.3% | -612K+62.5% | -1.63M+90.2% | ||
| Capital expenditure | 158K+259.1% | 44.0K-70.5% | 149K-75.7% | 612K+5000.0% | 12.0K-33.3% | |
| Free cash flow | -70.5M+3.8% | -73.2M-19.2% | -61.4M-87.9% | -32.7M+30.1% | -46.8M-25.0% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Proceeds from sale of PP&E | 213K | 0.00 | — | — | — | |
| 219M+64.4% | 133M-43.2% | 234M+13123.1% | -1.80M-103.7% | 49.1M-49.3% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00-100.0% | 161M | 0.00 | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Income taxes paid | 0.00-100.0% | 209K | 0.00 | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 921M-16.5% | 1.10B+93.3% | 570M+430.5% | 108M+81.8% | 59.1M-84.7% | |
| P/B | 2.0×-43.7% | 3.6×+63.3% | 2.2× | — | — | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: ELVN’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ELVN filings on SEC EDGAR → Not investment advice.